APOE and Alzheimer disease: Another study aims to investigate the efficacy and safety of lecanemab in preclinical AD, including the participants with either a first-degree relative diagnosed with dementia onset before age 75 with at least one APOE4 allele or high Aβ levels in brain or CSF, by a designed therapeutic protocol (5 mg/kg every 2 weeks for 2 months, then 10 mg/kg every 2 weeks for 2 years, and 10 mg/kg every 4 weeks for 4.5 years), which may provide clinical evidence to determine its efficacy and safety for applying lecanemab in such patients (Swanson et al., 2018; Tian Hui Kwan et al., 2020).